Table of Content - Global Prostate Cancer Testing Market.pdf

1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
res
Focus on Test Type, Application, End
User, and Region
Analysis and Forecast: 2022-2032
December 2022
Global Prostate
Cancer Testing
Market -
A Regional and
Country Analysis
Table of Content

2
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
Table of Content
Executive Summary..........................................................................22
1. Markets .....................................................................................27
1.1 Product Definition............................................................................................28
1.1.1 Inclusion and Exclusion Criteria................................................................28
1.2 Market Scope ...................................................................................................28
1.2.1 Scope of the Study......................................................................................28
1.2.2 Key Questions Answered in the Report ....................................................29
1.3 Research Methodology ...................................................................................30
1.3.1 Global Prostate Cancer Testing Market: Research Methodology ...........30
1.3.2 Data Sources ...............................................................................................31
1.3.2.1 Primary Data Sources........................................................................................ 31
1.3.2.2 Secondary Data Sources................................................................................... 32
1.3.3 Market Estimation Model ............................................................................32
1.3.4 Criteria for Company Profiling ...................................................................34
1.4 Market: Overview.............................................................................................35
1.4.1 Market Definition .........................................................................................35
1.4.2 Market Footprint and Growth Potential .....................................................36
1.4.3 Future Potential ...........................................................................................37
1.4.4 COVID-19 Impact on Global Prostate Cancer Testing Market .................37
2. Industry Analysis ......................................................................39
2.1 Overview...........................................................................................................40
2.2 Legal Requirements and Framework in the U.S............................................40
2.2.1 National Comprehensive Cancer Network (NCCN) Guidelines ...............40
2.2.2 American Urological Association (AUA) ...................................................41
2.2.3 American Cancer Society (ACS) ................................................................43
2.2.4 U.S. Preventive Services Task Force (USPSTF) .......................................43
2.3 Legal Requirements and Framework in Europe............................................44
2.4 Legal Requirements and Framework in Asia-Pacific....................................45

4
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
2.4.1 China ............................................................................................................45
2.5 Patent Analysis................................................................................................46
2.5.1 Patent Filing Trend......................................................................................46
2.5.2 Patent Analysis (by Year) ...........................................................................46
2.5.3 Patent Analysis (by Region) .......................................................................47
2.5.4 Patent Analysis (by Country) .....................................................................47
3. Global Prostate Cancer Testing Market: Market Dynamics .........48
3.1 Overview...........................................................................................................49
3.1.1 Impact Analysis ...........................................................................................49
3.2 Market Drivers..................................................................................................50
3.2.1 Rising Prevalence of Prostate Cancer Globally........................................50
3.2.1.1 Disease Trend ................................................................................................... 50
3.2.1.2 Increasing Number of Prostate Cancer Screening and Testing ........................ 51
3.2.1.3 Government Initiatives Related to Prostate Cancer........................................... 52
3.2.2 Market Restraints ........................................................................................53
3.2.2.1 Probability of False Positive Results of Prostate Cancer Testing...................... 53
3.2.2.2 Clinical Gaps Related to Prostate Cancer Testing ............................................ 53
3.2.3 Market Opportunities ..................................................................................53
3.2.3.1 New Treatment Therapy and Technique for Prostate Cancer ........................... 53
4. Global Prostate Cancer Testing Market: Competitive
Landscape.................................................................................54
4.1 Overview...........................................................................................................55
4.2 Corporate Strategies .......................................................................................55
4.2.1 Mergers and Acquisitions...........................................................................55
4.2.2 Synergistic Activities ..................................................................................57
4.2.3 Business Expansions and Funding...........................................................58
4.3 Business Strategies ........................................................................................59
4.3.1 Product Launches and Approvals .............................................................59
4.3.2 Publications .................................................................................................61
4.3.3 Licenses and Agreements..........................................................................62

5
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
4.3.4 Other Activities............................................................................................63
4.4 Market Share Analysis ....................................................................................65
5. Global Prostate Cancer Testing Market (by Test Type), Value
($million), 2021-2032 .................................................................67
5.1 Overview...........................................................................................................68
5.2 Pre-biopsy Test................................................................................................69
5.2.1 Biomarker Test ............................................................................................70
5.2.1.1 Blood-Based ...................................................................................................... 72
5.2.1.2 Urine-Based....................................................................................................... 75
5.2.2 Imaging Test ................................................................................................77
5.3 Biopsy...............................................................................................................80
5.4 Post-Biopsy Test .............................................................................................82
5.4.1 Tissue-Based Biomarker Test ....................................................................83
6. Global Prostate Cancer Testing Market (by Application), Value
($Million), 2021-2032..................................................................85
6.1 Overview...........................................................................................................86
6.2 Clinical..............................................................................................................87
6.3 Research ..........................................................................................................88
7. Global Prostate Cancer Testing Market (by End User), Value
($Million), 2021-2032..................................................................90
7.1 Overview...........................................................................................................91
7.2 Cancer Research Institutes.............................................................................92
7.3 Diagnostic Laboratories..................................................................................93
7.4 Hospitals and Clinics ......................................................................................94
7.5 Ambulatory Surgical Centers (ASCs) ............................................................95
7.6 Others ...............................................................................................................96
8. Global Prostate Cancer Testing Market (by Region), Value
($Million), 2021-2032..................................................................97
8.1 Overview...........................................................................................................98
8.2 North America................................................................................................101
8.2.1 U.S. .............................................................................................................103

6
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
8.2.2 Canada .......................................................................................................105
8.3 Europe ............................................................................................................109
8.3.1 Germany.....................................................................................................111
8.3.2 France.........................................................................................................112
8.3.3 U.K. .............................................................................................................114
8.3.4 Italy .............................................................................................................116
8.3.5 Spain...........................................................................................................118
8.3.6 Netherlands................................................................................................119
8.3.7 Rest-of-Europe...........................................................................................121
8.4 Asia-Pacific ....................................................................................................124
8.4.1 China ..........................................................................................................126
8.4.2 Japan..........................................................................................................127
8.4.3 India............................................................................................................129
8.4.4 Australia.....................................................................................................130
8.4.5 South Korea ...............................................................................................132
8.4.6 Rest-of-Asia-Pacific (RoAPAC) ................................................................133
8.5 Latin America.................................................................................................137
8.5.1 Brazil...........................................................................................................138
8.5.2 Mexico ........................................................................................................140
8.5.3 Rest-of-Latin America ...............................................................................142
8.6 Rest-of-the-World (RoW)...............................................................................143
9. Company Profiles....................................................................144
9.1 Overview.........................................................................................................145
9.2 Abbott. ............................................................................................................146
9.2.1 Company Overview ...................................................................................146
9.2.2 Role of Abbott. in the Global Prostate Cancer Testing Market..............146
9.2.3 Key Competitors of the Company............................................................147
9.2.4 Financials...................................................................................................147
9.2.5 Key Insights about the Financial Health of the Company......................149
9.2.6 Analyst Perspective ..................................................................................149

7
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
9.3 Abcam plc.......................................................................................................150
9.3.2 Role of Abcam plc. in the Global Prostate Cancer Testing Market.......150
9.3.3 Key Customers of the Company ..............................................................152
9.3.5 Financials...................................................................................................152
9.4 Agilent Technologies, Inc. ............................................................................155
9.4.2 Role of Agilent Technologies, Inc. in the Global Prostate Cancer
Testing Market ...........................................................................................155
9.4.4 Financials...................................................................................................156
9.5 Bio-Techne. (ExoDx)......................................................................................160
9.5.2 Role of Bio-Techne. (ExoDx) in the Global Prostate Cancer Testing
Market.........................................................................................................160
9.5.4 Financials...................................................................................................161
9.5.6 Corporate Strategies.................................................................................163
9.5.7 Business Strategies ..................................................................................164
9.6 Cleveland Diagnostics, Inc. ..........................................................................165
9.6.2 Role of Cleveland Diagnostics, Inc. in the Global Prostate Cancer
Testing Market ...........................................................................................165

8
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
9.7 Danaher. (Beckman Coulter, Inc.) ................................................................167
9.7.2 Role of Danaher. (Beckman Coulter, Inc.) in the Global Prostate
Cancer Testing Market..............................................................................167
9.7.4 Financials...................................................................................................168
9.8 Exact Sciences Corporation .........................................................................172
9.8.2 Role of Exact Sciences Corporation in the Global Prostate Cancer
Testing Market ...........................................................................................172
9.8.5 Financials...................................................................................................173
9.9 F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.) .....................178
9.9.2 Role of F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
in the Global Prostate Cancer Testing Market ........................................178
9.9.4 Financials...................................................................................................180

9
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
9.10 H.U. Group Holdings, Inc. (Fujeribio)...........................................................184
9.10.2 Role of H.U. Group Holdings, Inc. (Fujeribio) in the Global Prostate
Cancer Testing Market..............................................................................184
9.10.4 Financials...................................................................................................185
9.11 mdxhealth.......................................................................................................188
9.11.2 Role of mdxhealth. in the Global Prostate Cancer Testing Market .......188
9.11.3 Financials...................................................................................................189
9.11.5.1 Mergers and Acquisitions ................................................................................ 190
9.12 Siemens Healthcare GmbH...........................................................................192
9.12.2 Role of Siemens Healthcare GmbH in the Global Prostate Cancer
Testing Market ...........................................................................................192
9.12.4 Financials...................................................................................................194
9.13 Myriad Genetics, Inc......................................................................................197
9.13.2 Role of Myriad Genetics, Inc. in the Global Prostate Cancer Testing
Market.........................................................................................................197

10
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
9.13.6 Financials...................................................................................................199
9.14 NeoGenomics Laboratories..........................................................................201
9.14.2 Role of NeoGenomics Laboratories. in the Global Prostate Cancer
Testing Market ...........................................................................................201
9.14.4 Financials...................................................................................................203
9.15 OPKO Health, Inc. (GenPath)........................................................................206
9.15.2 Role of OPKO Health, Inc. (GenPath) in the Global Prostate Cancer
Testing Market ...........................................................................................206
9.15.5 Financials...................................................................................................208
9.16 Veracyte, Inc...................................................................................................212
9.16.2 Role of Veracyte, Inc. in the Global Prostate Cancer Testing
Market.........................................................................................................212

11
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
9.16.5 Financials...................................................................................................214
9.17 Emerging Companies....................................................................................219
9.17.1 Exact imaging ............................................................................................219
9.17.2 Proteomedix...............................................................................................219
9.17.3 Gregor Diagnostics ...................................................................................220

12
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
List of Figures
Figure 1: Tests Related to Prostate Cancer
Figure 2: Global Prostate Cancer Testing Market Segmentation
Figure 3: Share of Global Prostate Cancer Testing Market (by Test Type), $Million, 2021 and 2032
Figure 4: Share of Global Prostate Cancer Testing Market (by Application), $Million, 2021 and 2032
Figure 5: Share of Global Prostate Cancer Testing Market (by End User), $Million, 2021 and 2032
Figure 6: Global Prostate Cancer Testing Market Segmentation
Figure 7: Global Prostate Cancer Testing Market: Research Methodology
Figure 8: Primary Research Methodology
Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
Figure 10: Top-Down Approach (Segment-Wise Analysis)
Figure 11: Workflow of Prostate Cancer Testing (NCCN Guidelines)
Figure 12: NCCN Guidelines for Prostate Cancer Propose Germline Testing for Patients
Figure 13: Year-Wise Analysis of Patents Related to Global Prostate Cancer Testing, January 2019-
November 2022
Figure 14: Region-Wise Analysis of Patents Related to Prostate Cancer Testing, January 2019-November
2022
Figure 15: Country-Wise Analysis of Patents Related to Prostate Cancer Testing, January 2019-November
2022
Figure 16: Global Prostate Cancer Testing Market - Market Dynamics
Figure 17: Likert Scale
Figure 18: Impact Analysis of Market Drivers and Market Challenges on the Global Prostate Cancer Testing
Market
Figure 19: Trend of New Cases and Death Rate Related to Prostate Cancer Market
Figure 20: Share of Key Developments, January 2019-November 2022
Figure 21: Share of Mergers and Acquisitions (by Company), January 2019-November 2022
Figure 22: Share of Synergistic Activities (by Company), January 2019-November 2022
Figure 23: Number of Business Expansions and Funding Activities (by Company), January 2019-November
2022
Figure 24: Number of Product Launches and Approvals (by Company), January 2019-November 2022
Figure 25: Share of Publications (by Company), January 2019-November 2022
Figure 26: Number of Licenses and Agreements (by Company), January 2019-November 2022

13
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
Figure 27: Number of Other Activities (by Company), January 2019-November 2022
Figure 28: Market Share Analysis of Global Prostate Cancer Testing Market (Pre-Biopsy Testing), 2021
Figure 29: Market Share Analysis of Global Prostate Cancer Testing Market (Post-Biopsy Tissue Testing),
2021
Figure 30: Global Prostate Cancer Testing Market (by Test Type)
Figure 31: Share of Global Prostate Cancer Testing Market (by Test Type), $Million, 2021 and 2032
Figure 32: Global Prostate Cancer Testing Market (Pre-Biopsy Test), $Million, 2021-2032
Figure 33: Phases of Biomarker
Figure 34: Classification of Biomarker
Figure 35: Biomarker Test: Prostate Cancer
Figure 36: Biomarker Testing: Goals
Figure 37: Global Prostate Cancer Testing Market (Biomarker Test), $Million, 2021-2032
Figure 38: Global Prostate Cancer Testing Market (Blood-Based), $Million, 2021-2032
Figure 39: Global Prostate Cancer Testing Market (Urine-Based), $Million, 2021-2032
Figure 40: Advantages of Imaging Test: Prostate Cancer
Figure 41: Imaging Test: Prostate Cancer
Figure 42: Advantages of mp-MRI
Figure 43: Global Prostate Cancer Testing Market (Imaging Test), $Million, 2021-2032
Figure 44: Uses of TRUS-Based Biopsy
Figure 45: Prostate Biopsy Methods
Figure 46: Global Prostate Cancer Testing Market (Biopsy), $Million, 2021-2032
Figure 47: Global Prostate Cancer Testing Market (Post-Biopsy Test), $Million, 2021-2032
Figure 48: Utility of Tissue-Based Biomarker in Prostate Cancer Management
Figure 49: Global Prostate Cancer Testing Market (Tissue-Based Biomarker Test), $Million, 2021-2032
Figure 50: Share of global Prostate Cancer Testing Market (by Application), $Million, 2021 and 2032
Figure 51: Global Prostate Cancer Testing Market (Clinical), $Million, 2021-2032
Figure 52: Global Prostate Cancer Testing Market (Research), $Million, 2021-2032
Figure 53: Global Prostate Cancer Testing Market (by End User)
Figure 54: Share of Global Prostate Cancer Testing Market (by End User), $Million, 2021 and 2032
Figure 55: Global Prostate Cancer Testing Market (Cancer Research Institute), $Million, 2021-2032
Figure 56: Global Prostate Cancer Testing Market (Diagnostic Laboratories), $Million, 2021-2032
Figure 57: Global Prostate Cancer Testing Market (Hospitals and Clinics), $Million, 2021-2032
Figure 58: Global Prostate Cancer Testing Market (Ambulatory Surgical Centers), $Million, 2021-2032

14
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
Figure 59: Global Prostate Cancer Testing Market (Others), $Million, 2021-2032
Figure 60: Global Prostate Cancer Testing Market Snapshot (by Region)
Figure 61: Global Prostate Cancer Testing Market (by Region), $Million, 2022-2032
Figure 62: North America Prostate Cancer Testing Market, $Million, 2022-2032
Figure 63: North America: Market Dynamics
Figure 64: North America Prostate Cancer Testing Market (by Country), $Million, 2021-2032
Figure 65: U.S. Prostate Cancer Testing Market, $Million, 2021-2032
Figure 66: U.S. Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 67: Canada Prostate Cancer Testing Market, $Million, 2022-2032
Figure 68: Canada Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 69: Europe Prostate Cancer Testing Market, $Million, 2022-2032
Figure 70: Europe: Market Dynamics
Figure 71: Europe Prostate Cancer Testing Market (by Country), $Million, 2021-2032
Figure 72: Germany Prostate Cancer Testing Market, $Million, 2021-2032
Figure 73: Germany Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 74: France Prostate Cancer Testing Market, $Million, 2021-2032
Figure 75: France Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 76: U.K. Prostate Cancer Testing Market, $Million, 2021-2032
Figure 77: U.K. Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 78: Italy Prostate Cancer Testing Market, $Million, 2021-2032
Figure 79: Italy Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 80: Spain Prostate Cancer Testing Market, $Million, 2021-2032
Figure 81: Spain Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 82: Netherlands Prostate Cancer Testing Market, $Million, 2021-2032
Figure 83: Netherlands Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 84: Rest-of-Europe Prostate Cancer Testing Market, $Million, 2021-2032
Figure 85: Rest-of-Europe Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 86: Asia-Pacific Prostate Cancer Testing Market, $Million, 2022-2032
Figure 87: Asia-Pacific: Market Dynamics
Figure 88: Asia-Pacific Prostate Cancer Testing Market (by Country), $Million, 2021-2032
Figure 89: China Prostate Cancer Testing Market, $Million, 2021-2032
Figure 90: China Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 91: Japan Prostate Cancer Testing Market, $Million, 2021-2032

15
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
Figure 92: Japan Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 93: India Prostate Cancer Testing Market, $Million, 2021-2032
Figure 94: India Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 95: Australia Prostate Cancer Testing Market, $Million, 2021-2032
Figure 96: Australia Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 97: South Korea Prostate Cancer Testing Market, $Million, 2021-2032
Figure 98: South Korea Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 99: Rest-of-Asia-Pacific Korea Prostate Cancer Testing Market, $Million, 2021-2032
Figure 100: Rest-of-Asia-Pacific Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 101: Latin America Prostate Cancer Testing Market, $Million, 2022-2032
Figure 102: Latin America: Market Dynamics
Figure 103: Latin America Prostate Cancer Testing Market (by Country), $Million, 2021-2032
Figure 104: Brazil Prostate Cancer Testing Market, $Million, 2021-2032
Figure 105: Brazil Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 106: Mexico Prostate Cancer Testing Market, $Million, 2021-2032
Figure 107: Mexico Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 108: Rest-of-Latin America Prostate Cancer Testing Market, $Million, 2021-2032
Figure 109: Rest-of-Latin America Prostate Cancer Testing Market (by Test Type), $Million, 2021-2032
Figure 110: Rest-of-the-World Prostate Cancer Testing Market, $Million, 2022-2032
Figure 111: Total Number of Companies Profiled
Figure 112: Abbott.: Product Portfolio
Figure 113: Abbott.: Overall Financials, $Million, 2019-2021
Figure 114: Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 115: Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 116: Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 117: Abcam plc.: Product Portfolio
Figure 118: Abcam plc.: Overall Financials, $Million, 2018-2020
Figure 119: Abcam plc.: Revenue (by Segment), $Million, 2019-2020
Figure 120: Abcam plc.: Revenue (by Region), $Million, 2018-2020
Figure 121: Abcam plc.: R&D Expenditure, $Million, 2019-2021
Figure 122: Agilent Technologies, Inc.: Product Portfolio
Figure 123: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
Figure 124: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021

16
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
Figure 125: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 126: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
Figure 127: Bio-Techne. (ExoDx): Product Portfolio
Figure 128: Bio-Techne. (ExoDx): Overall Financials, $Million, 2020-2022
Figure 129: Bio-Techne. (ExoDx): Revenue (by Segment), $Million, 2020-2022
Figure 130: Bio-Techne. (ExoDx): Revenue (by Region), $Million, 2020-2022
Figure 131: Bio-Techne. (ExoDx): R&D Expenditure, $Million, 2020-2022
Figure 132: Cleveland Diagnostics, Inc.: Product Portfolio
Figure 133: Danaher. (Beckman Coulter, Inc.): Product Portfolio
Figure 134: Danaher. (Beckman Coulter, Inc.): Overall Financials, $Million, 2019-2021
Figure 135: Danaher. (Beckman Coulter, Inc.): Revenue (by Segment), $Million, 2019-2021
Figure 136: Danaher. (Beckman Coulter, Inc.): Revenue (by Region), $Million, 2019-2021
Figure 137: Danaher. (Beckman Coulter, Inc.): R&D Expenditure, $Million, 2019-2021
Figure 138: Exact Sciences Corporation: Product Portfolio
Figure 139: Exact Sciences Corporation: Overall Financials, $Million, 2019-2021
Figure 140: Exact Sciences Corporation.: Revenue (by Segment), $Million, 2019-2021
Figure 141: Exact Sciences Corporation: Revenue (by Region), $Million, 2019-2021
Figure 142: Exact Sciences Corporation: R&D Expenditure, $Million, 2019-2021
Figure 143: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Product Portfolio
Figure 144: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Overall Financials, $Million,
2019-2021
Figure 145: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Segment), $Million,
2019-2021
Figure 146: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): Revenue (by Region), $Million,
2019-2021
Figure 147: F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.): R&D Expenditure, $Million,
2019-2021
Figure 148: H.U. Group Holdings, Inc. (Fujeribio): Product Portfolio
Figure 149: H.U. Group Holdings, Inc. (Fujeribio): Overall Financials, $Million, 2018-2020
Figure 150: H.U. Group Holdings, Inc. (Fujeribio): Revenue (by Segment), $Million, 2019-2021
Figure 151: H.U. Group Holdings, Inc. (Fujeribio): R&D Expenditure, $Million, 2018-2020
Figure 152: mdxhealth.: Product Portfolio
Figure 153: mdxhealth.: Overall Financials, $Million, 2019-2021

17
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
Figure 154: mdxhealth.: Revenue (by Segment), $Million, 2019-2021
Figure 155: mdxhealth.: R&D Expenditure, $Million, 2019-2021
Figure 156: Siemens Healthcare GmbH: Product Portfolio
Figure 157: Siemens Healthcare GmbH: Overall Financials, $Million, 2019-2021
Figure 158: Siemens Healthcare GmbH: Revenue (by Segment), $Million, 2019-2021
Figure 159: Siemens Healthcare GmbH: Revenue (by Region), $Million, 2019-2021
Figure 160: Siemens Healthcare GmbH: R&D Expenditure, $Million, 2019-2021
Figure 161: Myriad Genetics, Inc.: Product Portfolio
Figure 162: Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021
Figure 163: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 164: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 165: NeoGenomics Laboratories.: Product Portfolio
Figure 166: NeoGenomics Laboratories.: Overall Financials, $Million, 2019-2021
Figure 167: NeoGenomics Laboratories.: Revenue (by Segment), $Million, 2019-2021
Figure 168: NeoGenomics Laboratories.: R&D Expenditure, $Million, 2019-2021
Figure 169: OPKO Health, Inc. (GenPath): Product Portfolio
Figure 170: OPKO Health, Inc. (GenPath): Overall Financials, $Million, 2019-2021
Figure 171: OPKO Health, Inc. (GenPath): Revenue (by Segment), $Million, 2019-2021
Figure 172: OPKO Health, Inc. (GenPath): R&D Expenditure, $Million, 2019-2021
Figure 173: Veracyte, Inc.: Product Portfolio
Figure 174: Veracyte, Inc.: Overall Financials, $Million, 2019-2021
Figure 175: Veracyte, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 176: Veracyte, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 177: Veracyte, Inc: R&D Expenditure, $Million, 2019-2021

18
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
List of Tables
Table 1: Impact Analysis of Market Drivers, Restraints, and Opportunities on the Global Prostate Cancer
Testing Market
Table 2: Likert Scale
Table 3: Numerous Risk Categories for Clinically Localized Prostate Cancer
Table 4: Estimated Number of Deaths in 2018 and in 2040
Table 5: Recommendations Related to Prostate Cancer Screening
Table 6: Blood-Based Biomarkers for Prostate Cancer
Table 7: Guidance and Age Recommendations: Prostate Cancer
Table 8: Urine-Based Biomarkers for Prostate Cancer
Table 9: PCA3 Test Score
Table 10: Tissue-Based Biomarkers for Prostate Cancer

19
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have the vision to be a leading and preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

20
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published, or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates, and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties, and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

21
G
L
O
B
A
L
P
R
O
S
T
A
T
E
C
A
N
C
E
R
T
E
S
T
I
N
G
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Table of Content - Global Prostate Cancer Testing Market.pdf

Recommended

Recommended

More Related Content

Similar to Table of Content - Global Prostate Cancer Testing Market.pdf

Similar to Table of Content - Global Prostate Cancer Testing Market.pdf (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Table of Content - Global Prostate Cancer Testing Market.pdf